Captodiame
From Wikipedia, the free encyclopedia
 |
|
|
Captodiame
|
|
| Systematic (IUPAC) name | |
| 2-[(4-butylsulfanylphenyl)-phenyl-methyl] sulfanyl-N,N-dimethylethanamine |
|
| Identifiers | |
| CAS number | |
| ATC code | N05 |
| PubChem | |
| Chemical data | |
| Formula | C21H29NS2 |
| Mol. mass | 359.594 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Captodiame (INN, also known as captodiamine) is an anxiolytic. It is a derivative of diphenhydramine.[1]
A 2004 study suggested captodiame may be helpful in preventing benzodiazepine withdrawal syndrome in people discontinuing benzodiazepine treatment.[1]
[edit] References
- ^ a b Mercier-Guyon C, Chabannes JP, Saviuc P (2004). "The role of captodiamine in the withdrawal from long-term benzodiazepine treatment". Curr Med Res Opin 20 (9): 1347–55. doi:. PMID 15383182. Free full text with registration
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||||||||
